UBS Group AG Reduces Position in Xeris Biopharma Holdings, Inc. $XERS

UBS Group AG cut its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 66.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 601,834 shares of the company’s stock after selling 1,180,900 shares during the quarter. UBS Group AG’s holdings in Xeris Biopharma were worth $4,724,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after purchasing an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd boosted its stake in shares of Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Millennium Management LLC boosted its position in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Xeris Biopharma by 38.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,698,757 shares of the company’s stock valued at $13,828,000 after buying an additional 470,798 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $6.23, for a total value of $103,835.41. Following the completion of the sale, the insider owned 1,193,173 shares in the company, valued at approximately $7,433,467.79. The trade was a 1.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Aloysius Brady sold 10,834 shares of the business’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the sale, the director owned 89,166 shares of the company’s stock, valued at approximately $493,979.64. This represents a 10.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 60,835 shares of company stock valued at $367,860. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Trading Up 2.4%

NASDAQ:XERS opened at $6.38 on Friday. Xeris Biopharma Holdings, Inc. has a one year low of $4.30 and a one year high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm has a market cap of $1.10 billion, a P/E ratio of 106.33 and a beta of 0.85. The firm has a 50-day simple moving average of $5.95 and a 200-day simple moving average of $6.74.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.80.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.